| Literature DB >> 24718306 |
Marian Loveday1, Nesri Padayatchi2, Kristina Wallengren3, Jacquelin Roberts4, James C M Brust5, Jacqueline Ngozo6, Iqbal Master7, Anna Voce8.
Abstract
OBJECTIVE: To improve the treatment of MDR-TB and HIV co-infected patients, we investigated the relationship between health system performance and patient treatment outcomes at 4 decentralised MDR-TB sites.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24718306 PMCID: PMC3981751 DOI: 10.1371/journal.pone.0094016
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Framework to monitor health system factors at 4 decentralised MDR-TB sites.
| Sub-domains | Indicators measuring local site health system factors |
| Health system factors | |
|
| |
| District level: Leadership and ownership | MDR-TB perceived as a district problem and not as an MDR-TB unit problem. |
| District prioritises spending on MDR-TB programme. | |
| District level support: Managerial, administrative, technical | Staff at PHC sites adequately trained to manage down-referred MDR-TB patients. |
| Regular visits by district TB co-ordinator. | |
| Facility level support | Staff at MDR-TB unit feel supported by facility managers. |
|
| |
| Integrated services: MDR-TB and HIV | Integrated services |
| Integrated clinical notes | |
| Integrated services: MDR-TB and PHC | Mobile clinics re-organised to ensure tracing of TB/MDR-TB defaulters and injecting MDR-TB patients at home. |
| Integrated services: MDR-TB and TB | Communication system for discussing and solving problems with down-referral. |
|
| |
| Human Resources (HR) | Availability of staff |
| Knowledge | |
| Stability and consistency (including staff rotation) | |
| Managerial support | |
| Support services (SS) | Pharmaceutical: Availability of drugs |
| Laboratory: Culture turnaround time | |
| Transport: Needs satisfaction – Percentage of transport requests met | |
| Equipment: Availability, functionality and utilisation | |
|
| |
| Continuity of care | Referral system: Treatment initiation delay |
| Mechanism for following up defaulters | |
| Monitoring and evaluation system in place: MDR-TB register up to date | |
| Quality of care | Availability of clinical guidelines |
| Adherence to guidelines: Audit of clinic notes (clinical skills) | |
| Clinical notes adequate and complete: Audit of clinic notes (clinical skills) | |
| Utilisation of clinical expertise at centralised, specialised hospital: Audit telephone calls to doctors at centralised hospital | |
| Management of serious adverse events immediate and appropriate |
Examples of Indicators with measurement and scoring systems.
| Criteria for measurement/Indicators | Evidence | Scoring system |
|
| ||
| MDR-TB perceived as a district programme and not as an MDR-TB unit programme. | Documented evidence:Minutes of quarterly | Yes or noDate this started |
| MDR-TB reported and discussed in quarterly district TB meetings | district TB meetings | Consistency |
|
| ||
| % TB and HIV co-infected patients receive MDR-TB/HIV consultationand management at one desk | Observation | Yes or noDate this started |
| Consistency | ||
| % co-infected patients who do not queue at pharmacy | Observation | Yes or noDate this started |
| Consistency | ||
| % clinical notes of co-infected patients which on discharge detail referral for ART | Audit of clinic notes | Yes or noDate this started |
| Consistency | ||
|
| ||
| % mobile clinics re-organised to ensure tracing of TB/MDR-TB defaulters andinjecting MDR-TB patients at home | Transport audit | No. of vehicles Date this started |
| Vehicle logs | Consistency | |
|
| ||
| Mechanism for following up defaulters: % patients who miss visits who arefollowed up and his is documented in folder | Audit of clinic notes | Yes or no |
Scores allocated for health system factors at the 4 decentralised sites.
| Health system factor | Indicator | Maximum scorepossible | Site1 | Site2 | Site3 | Site4 |
|
| ||||||
| District level: Leadership and | MDR-TB perceived as a district problem and notas an MDR-TB unit problem | 8 | 8 | 0 | 0 | 3 |
| ownership | District prioritises spending on MDR-TB programme | 5 | 3 | 1 | 1 | 1 |
| District level support:Managerial, technical | Staff at PHC sites adequately trained to manageMDR-TB down-referred patients | 8 | 6 | 3 | 2 | 3 |
| + administrative | Regular visits by district TB co-ordinator | 5 | 2 | 0 | 0 | 1 |
| Facility level support | MDR-TB unit staff feel supported by facility managers | 3 | 2 | 0 | 0 | 0 |
| Total context score | 29 | 21 | 4 | 3 | 8 | |
|
|
|
|
|
|
| |
|
| ||||||
|
| Integrated services | 13 | 13 | 9 | 7 | 6 |
| Integrated clinical notes | 8 | 8 | 5 | 5 | 3 | |
| Integrated MDR-TB and PHC | Mobile clinics re-organised to ensure tracing ofTB/MDR-TBdefaulters and injecting MDR-TB patients at home. | 8 | 8 | 5 | 3 | 0 |
| Integrated MDR-TB and TB | Communication system for discussing andsolving problems with down-referral | 3 | 3 | 2 | 0 | 3 |
| Total integration score | 32 | 32 | 21 | 15 | 12 | |
|
|
|
|
|
|
| |
|
| ||||||
| Human resources | Availability of staff | 10 | 2 | 7 | 7 | 5 |
| Knowledge | 3 | 3 | 3 | 1 | 3 | |
| Stability and consistency | 4 | 4 | 2 | 2 | 2 | |
| Managerial support | 4 | 4 | 3 | 0 | 0 | |
| Support services | Pharmaceutical: Availability of drugs | 4 | 3 | 0 | 3 | 2 |
| Laboratory: Culture turnaround time | 8 | 8 | 8 | 5 | 1 | |
| Transport: Needs satisfaction - % of transport requests met | 1 | 1 | 0 | 1 | 0 | |
| Equipment: Availability and utilisation | 5 | 5 | 3 | 1 | 1 | |
| Total mechanism score | 39 | 30 | 26 | 20 | 14 | |
|
|
|
|
|
|
| |
|
| ||||||
| Continuity of care | Referral system: Treatment initiation delay | 9 | 4 | 4 | 4 | 2 |
| Mechanism for following up defaulters | 3 | 3 | 3 | 2 | 3 | |
| M+E system in place: MDR register up to date | 3 | 3 | 2 | 2 | 2 | |
| Quality of care | Availability of clinical guidelines | 5 | 5 | 1 | 3 | 2 |
| Adherence to guidelines: Audit of clinic notes | 3 | 1 | 0 | 0 | 0 | |
| Clinical notes adequate and complete: Audit of clinic notes | 3 | 3 | 2 | 2 | 1 | |
| Utilisation of clinical expertise at KGV:Audit telephone calls to KGV doctors | 3 | 3 | 1 | 2 | 1 | |
| Management of serious adverse events immediate and appropriate | 6 | 6 | 6 | 6 | 6 | |
| Total output score | 35 | 28 | 19 | 21 | 17 | |
|
|
|
|
|
|
| |
Treatment outcome definitions*.
| Treatment outcome | Definitions |
| Cure | Cure was defined as completion of treatment and ≥5 consecutivenegative culture results in the final 12 months of treatment. |
| Treatment completion | Treatment completion referred to completion of therapy but withoutbacteriologic documentation of cure. |
| Treatment success | Treatment success has been defined as the percentage of patients in whom the treatment outcomewas either cured or completed. That is, “% successful = no. of patientscured+no. of patients completed treatment/Total no. initiated treatment×100”. |
| Treatment failure | Treatment failure was defined as having more than one positive culture in the final 12 months of therapy,or if any one of the final three cultures was positive, or if more than one drug in the treatment regimen was replaced,or if treatment was terminated due to adverse events or no clinical improvement. |
| Default | Default was defined as an interruption in treatment for ≥2 consecutive months for any reason. |
| Death | Death was defined as all-cause mortality during MDR-TB treatment. |
| Unsuccessful treatment | Unsuccessful treatment outcome has been defined as the percentage of patients in whom the treatmentoutcome was died, defaulted, or failed treatment. |
| Transferred out | Transferred out: A patient with MDR-TB who was transferred to another reporting andrecording unit a year after study-enrolment whose treatment outcome is unknown. |
*Treatment outcome definitions used are WHO definitions for the management of MDR-TB. [17], [18]
Treatment outcomes of patients with MDR-TB treated at 4 decentralised sites in KwaZulu-Natal, South Africa*.
| Treatment Outcomes | Site 1 | Site 2 | Site 3 | Site 4 |
| All decentralized hospitals |
| n = 125 | n = 148 | n = 202 | n = 261 | n = 736 | ||
| Treatment success | 90 (72.0) | 89 (60.1) | 113 (55.9) | 135 (51.7) | <0.01 | 427 (58.0) |
| Died | 17 (13.6) | 22 (14.9) | 25 (12.4) | 69 (26.4) | <0.01 | 133 (18.1) |
| Failed | 7 (5.6) | 11 (7.4) | 12 (5.9) | 19 (7.3) | 0.87 | 49 (6.7) |
| Defaulted | 9 (7.2) | 20 (13.5) | 50 (24.8) | 28 (10.7) | <0.01 | 107 (14.5) |
Data are number (%), unless otherwise indicated.
*Treatment outcome definitions used are WHO definitions, as defined in Table 4.
Figure 1Breakdown of total health systems performance score by domain at 4 decentralised MDR-TB sites.
The four sites are plotted on the X-axis and the health system performance score on the Y-axis. Health system performance is the sum (cumulative score) of the four different domains (output, mechanism, integration and context), which are shaded differently. Site 1 had the highest score of 132 which comprised scores of 32 for the output domain, 31 for the mechanism domain, 40 for the integration domain and 29 for the context domain.
Correlation between health system performance and successful treatment outcomes for each domain for MDR-TB patients treated at 4 decentralised sites.
| Pearson Correlation Coefficient, r | p-value | |
| Total | 0.99 | 0.01 |
| Context | 0.82 | 0.18 |
| Integration | 0.99 | <0.01 |
| Output | 0.94 | 0.06 |
| Mechanism | 0.93 | 0.07 |
| Human resources (HR) | 0.42 | 0.58 |
| Support services (SS) | 0.96 | 0.04 |
Figure 2Association between successful treatment outcomes and total health systems performance score at 4 decentralised MDR-TB sites.
This figure shows the association between successful treatment outcomes and total health systems performance score. The percentage of successful treatment outcomes is plotted on the Y-axis and the health performance score on the X-axis. From the graph it can be seen that Site 1 had the highest treatment success and highest total health system performance score. Sites 2, 3 and 4 can be seen to have lower health system performance scores and lower rates of treatment success. This graph shows there was an association between successful treatment outcomes and total Health System Performance score (r = 0.99) and that this association was significant (p<0.01).